Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (1): 26-29.doi: 10.6040/j.issn.1671-7554.0.2018.1151

Previous Articles    

Clinical management of oligometastatic prostate cancer

HAN Bangmin, JING Yifeng   

  1. Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, China
  • Published:2022-09-27

PDF (PC)

22

Abstract: Oligometastatic prostate cancer may be a special stage of prostate cancer progression. Positive treatment of oligometastatic prostate cancer may achieve good results. However, there is still a lack of understanding and controversy about it. This article reviews the definition, diagnosis and management of oligometastatic prostate cancer.

Key words: Prostate cancer, Oligometastatic, Cytoreductive radical prostatectomy, Metastasis-directed therapy

CLC Number: 

  • R737
[1] Hellman S, Weichselbaum RR. Oligometastases[J]. J Clin Oncol, 1995, 13(1): 8-10.
[2] Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC, 2017[J]. Eur Urol, 2018, 73(2): 178-211.
[3] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2017, 71(4): 618-629.
[4] deSouza NM, Liu Y, Chiti A, et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group[J]. Eur J Cancer, 2018, 91: 153-163. doi:10.1016/j.ejca.2017.12.012.
[5] Clement JM, Sweeney CJ. Evolving treatment of oligometastatic hormone-sensitive prostate cancer[J]. J Oncol Pract, 2017, 13(1): 9-18.
[6] Löfgren J, Mortensen J, Rasmussen SH, et al. A prospective study comparing 99mTc-hydroxyethylene-diphosphonate planar bone scintigraphy and whole-body SPECT/CT with 18F-fluoride PET/CT and 18F-fluoride PET/MRI for diagnosing bone metastases[J]. J Nucl Med, 2017, 58(11): 1778-1785.
[7] Hövels AM, Heesakkers RAM, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis[J]. Clin Radiol, 2008, 63(4): 387-395.
[8] Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer[J]. Theranostics, 2012, 2(3): 318-330.
[9] Fendler WP, Calais J, Allen-Auerbach M, et al.68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study[J]. J Nucl Med, 2017, 58(10): 1617-1623.
[10] Corfield J, Perera M, Bolton D, et al. 68Ga-prostate specific membrane antigen(PSMA)positron emission tomography(PET)for primary staging of high-risk prostate cancer: a systematic review[J]. World J Urol, 2018, 36(4): 519-527.
[11] Zattoni F, Zattoni F, Evangelista L. Re: marlon perera, nathan papa, daniel christidis, et al. sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016; 70: 926-37[J]. Eur Urol, 2017, 71(2): e64-e65. doi:10.1016/j.eururo.2016.08.049.
[12] von Eyben FE, Picchio M, von Eyben R, et al. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis[J]. Eur Urol Focus, 2018, 4(5): 686-693.
[13] Thompson IM, Tangen C, Basler J, et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease[J]. J Urol, 2002, 168(3): 1008-1012.
[14] Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry[J]. Eur Urol, 2014, 66(3): 602-603.
[15] Bayne CE. Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65: 1058-66[J]. Eur Urol, 2014, 65(6): e99. doi:10.1016/j.eururo.2013.12.060.
[16] Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study[J]. J Urol, 2015, 193(3): 832-838.
[17] Sooriakumaran P, Karnes J, Stief C, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation[J]. European Urology, 2016, 69(5): 788-794.
[18] Gandaglia G, Fossati N, Stabile A, et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up[J]. Eur Urol, 2017, 72(2): 289-292.
[19] Wiegand LR, Hernandez M, Pisters LL, et al. Surgical management of lymph-node-positive prostate cancer: improves symptomatic control[J]. BJU Int, 2011, 107(8): 1238-1242.
[20] Won AC, Gurney H, Marx G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer[J]. BJU Int, 2013, 112(4): E250-E255. doi:10.1111/bju.12169.
[21] Jereczek-Fossa BA, Fariselli L, Beltramo G, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer[J]. Radiother Oncol, 2009, 93(1): 14-17.
[22] Muacevic A, Kufeld M, Rist C, et al. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer[J]. Urol Oncol, 2013, 31(4): 455-460.
[23] Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer[J]. Front Oncol, 2012, 2: 215. doi:10.3389/fonc.2012.00215.
[24] Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy[J]. Clin Genitourin Cancer, 2013, 11(1): 27-32.
[25] Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence[J]. Radiat Oncol, 2014, 9: 135. doi:10.1186/1748-717X-9-135.
[26] Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial[J]. J Clin Oncol, 2018, 36(5): 446-453.
[27] Siva S, Bressel M, Murphy DG, et al. Stereotactic abative body radiotherapy(SABR)for oligometastatic prostate cancer: a prospective clinical trial[J]. Eur Urol, 2018, 74(4): 455-462.
[28] Oertel M, Scobioala S, Kroeger K, et al. Worth a local treatment? -Analysis of modern radiotherapy concepts for oligometastatic prostate cancer[J]. Radiat Oncol, 2018, 13: 185. doi:10.1186/s13014-018-1118-7.
[29] Cattrini C, Zanardi E, Boccardo F. Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer[J]. J Clin Oncol, 2018, 36(22): 2350. doi:10.1200/JCO.2018.78.0031.
[1] XU Zhen, DIAO Tongxiang, ZANG Zhenjie, SHAO Dingchang, ZHANG Qi, SUN Dingqi, FU Qiang. Value of isoform［-2］proprostate-specific antigen and its derivatives in the diagnosis of prostate cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 51-56.
[2] SUN Haoyu, JIANG Xin, CHEN Shouzhen, QU Sifeng, SHI Benkang. Multiparametric magnetic resonance imaging combined with prostate health index in the diagnosis of prostate cancer in 142 patients within PSA grey zone [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 46-50.
[3] Benkang SHI,Shouzhen CHEN,Sifeng QU,Yong WANG,Lei LIU. Research progress and clinical characteristics of clinical rapidly progressing prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 110-116.
[4] XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110.
[5] SUN Dingqi, FU Qiang, ZHANG Hui, LIU Shuai, DIAO Tongxiang, CAO Qingwei, ZHANG Keqin. Clinical value of targeted multiparameter MRI and transrectal ultrasonography fusion prostate biopsy for the detection of PI-RADS≥3 prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 108-113.
[6] LÜ Jiaju, HU Jialin, DING Sentai. Advances in focal therapy for prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 1-5.
[7] ZHOU Fangjian, HUANG Hua, LI Yonghong. Focal cryoablation for prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 6-10.
[8] ZHU Gang, ZHANG Kai. Chinese prostate cancer screening: current situation and challenges [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 11-15.
[9] YAO Xudong. Strategy and efficacy of surgical treatment in locally advanced prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 21-25.
[10] MAO Shaowei, LU Guoliang, LI Liang, XIA Qinghua. Valproic acid augments the anti-tumor potential of metformin in PC-3 cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(3): 48-53.
[11] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[12] ZHAI Hongyun, ZHANG Denglu, WANG Guangjie, KONG Feng, CHENG Guanghui, ZHAO Shengtian. Effects of factors secreted by mouse embryonic stem cells on prostate cancer cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 8-12.
[13] DING Huan1, SUN Ying1, LI Xiao-qing2, LI Li1. Effect of PARP inhibitor combined with Gemcitabine or Docetaxel on the  proliferation of androgen-independent prostate cancer cell line PC3 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 33-36.
[14] ZHENG Yi, JIANG Wei, JIN Xun-bo, WANG Mu-wen, ZHANG Yi-nan, XIA Qing-hua. Valproic acid induces autophagy and regulates the expression of  SPARCL1 protein in prostate cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(7): 32-35.
[15] GAO Feng-bin, SI Man-fei, LIU Yong-qing, NIU Lei-lei, YUAN Hui-qing. Retigeric acid B induced cell cycle arrest in human prostate cancer cells by upregulation of p21CIP1 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(12): 34-40.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd